PROVECTUS BIOPHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
PVCT$0.07+3.6%Stored close · as of Jun 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| Assets | ||
| Current Assets: | ||
| Cash | $18,035 | $76,576 |
| Restricted cash | 744,717 | 950,223 |
| Short-term receivables | 98 | 476 |
| Prepaid expenses and other current assets | 245,954 | 337,522 |
| Total Current Assets | 1,008,804 | 1,364,797 |
| Equipment and furnishings, less accumulated depreciation of $113,224 and $110,994, respectively | 9,789 | 12,020 |
| Operating lease right-of-use asset | 60,398 | 72,026 |
| Total Assets | $1,078,991 | $1,448,843 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable | $1,369,957 | $1,675,891 |
| Unearned grant revenue | 715,176 | 953,248 |
| Other accrued expenses | 3,096,272 | 3,240,436 |
| Accrued interest | 40,660 | 22,600 |
| Accrued interest - related parties | 110,914 | 123,828 |
| Notes payable | 190,910 | 277,815 |
| Convertible notes payable | 953,000 | 800,000 |
| Convertible notes payable - related parties | 1,990,000 | 1,875,000 |
| Operating lease liability, current portion | 49,020 | 48,077 |
| Total Current Liabilities | 8,515,909 | 9,016,895 |
| Operating lease liability, non-current portion | 12,729 | 25,299 |
| Total Liabilities | 8,528,638 | 9,042,194 |
| Commitments, contingencies, and litigations (Note 12) | - | |
| Stockholders’ Deficit: | ||
| Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series D Convertible Preferred Stock; 12,374,000 shares designated; 12,373,247 shares issued and outstanding at March 31, 2024 and December 31, 2023; aggregate liquidation preference of $14,164,889 at March 31, 2024 and December 31, 2023 | 12,373 | 12,373 |
| Series D-1 Convertible Preferred Stock; 11,241,000 shares designated; 10,587,571 and 10,361,097 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $121,205,780 and $118,613,136 at March 31, 2024 and December 31, 2023, respectively | 10,587 | 10,361 |
| Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,522,119 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 419,522 | 419,522 |
| Additional paid-in capital | 245,362,902 | 244,714,967 |
| Accumulated other comprehensive loss | (60,580) | (60,165) |
| Accumulated deficit | (253,194,451) | (252,690,409) |
| Total Stockholders’ Deficit | (7,449,647) | (7,593,351) |
| Total Liabilities and Stockholders’ Deficit | $1,078,991 | $1,448,843 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.